Not Available

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$299,881.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000095
Agency Tracking Number:
N43CO201000095
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
STC BIOLOGICS, INC
182 ELM ST, UNIT 3, CAMBRIDGE, MA, 02139-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
829731814
Principal Investigator:
MAGDALENA LESZCZYNIECKA
(617) 899-0724
mleszczyniecka@stcbiologics.com
Business Contact:
Research Institution:
n/a
Abstract

The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic version of this drug would make cancer treatment more affordable to a wider segment of the population and lower the cost burden on government-sponsored healthcare programs.  STC Biologics Inc. is uniquely positioned to address the technical challenge of reverse engineering trastuzumab as its drug development platform offers rapid and efficient analysis of post-translational modification of recombinant proteins.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government